BioSpace News Archive

Sage Therapeutics, Inc. announced the presentation of data that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was associated with improvements on multiple tests of executive functioning and learning and memory in patients with mild cognitive impairment due to Parkinson’s disease in the open label Phase 2 PARADIGM Study.

Ecolab Inc. (NYSE:ECL) announced a temporary 8%-12% energy surcharge on all of its global products, effective April 1, 2022.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2021 financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, March 29, 2022.

Sanofi and Blackstone announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has signed a binding term sheet with Meta Healthcare Ltd. to acquire the worldwide commercialization rights, except in the United Kingdom and Ireland, for a novel dosage form of a prescription drug already approved by the U.S. Food and Drug Administration and intended for the treatment of patients with phenylketonuria.

In February, just after the end of the quarter, we received feedback from the FDA, which means that we have a plan for our continued application process.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced interim Phase 1 clinical data for IDE397, a potential best in class methionine adenosyltransferase 2a inhibitor.

CB Scientific. Inc. announced that MaloneBailey, LLP has successfully concluded its annual audit of the Company in accordance with Public Company Accounting Oversight Board standards, and consequently issued their favorable Auditor’s Report on March 14, 2022.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the year ended December 31, 2021.